Attralus, a South San Francisco, CA-based biopharmaceutical company focused on creating medicines for systemic amyloidosis, raised $25m in Series A financing.
The round was led by venBio Partners.
The company intends to use the funds to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis. Attralus expects to file IND applications for the two therapeutics programs by early 2022.
Led by Spencer Guthrie, Chief Executive Officer, Attralus is a biopharmaceutical company whose proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. Attralus is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
The team also includes Jonathan Wall, Ph.D., Interim Chief Scientific Officer of Attralus, Professor of Medicine at the University of Tennessee Graduate School of Medicine, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program.
Richard Gaster, M.D., Ph.D., Partner at venBio, and Corey Goodman, Ph.D., Managing Partner at venBio, will join Attralus’s Board of Directors.